Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drug

Summary

Boulevard Bio secured $65M in funding to advance its immunology pipeline, which includes investigational drugs for IgAN and immune-resetting therapies discovered in-house, positioning itself to compete with existing treatments like Vera Therapeutics' offerings.